# GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

Source: https://onco.cc/trials/nct06948981/  
OnCo record `nct06948981` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GT719 Injection in non-Hodgkin lymphoma, run by Grit Biotechnology, now recruiting.

## Summary

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies is a phase 1/2 interventional study registered as NCT06948981 by Grit Biotechnology, with 46 participants planned, started 2025-04-18 and due to reach its primary completion in 2028-04-17. Interventions recorded: GT719 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06948981
- Phase: 1/2
- Setting: A Single-arm, Open-label, Phase I/II Clinical Study of GT719 Injection for Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
- Sponsor: Grit Biotechnology
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06948981: https://clinicaltrials.gov/study/NCT06948981

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct06948981.json